[Alpha Biz= Reporter Kim Jisun] According to Hanmi Pharmaceutical Group and industry sources, an interim board meeting of Hanmi Science is scheduled for the 14th. While the company has not disclosed the agenda of the board meeting, it has been reported in the industry that the agenda will include a discussion on the dismissal of Chairman Song Young-sook, who is also the co-CEO and the wife of the company's founder.
Earlier, at the end of March, during the regular shareholders' meeting, founder's son and daughter, Im Jong-yoon and Jong-hoon, won in a power struggle against their mother, Chairman Song, and returned to the management forefront. Subsequently, Im Jong-hoon became co-CEO of Hanmi Science with Chairman Song, and Im Jong-yoon was expected to take over as CEO of Hanmi Pharmaceutical. Recently, Chairman Song reportedly posted on the company's internal bulletin board, objecting to personnel decisions at Hanmi Science involving co-CEO Im Jong-hoon.
Currently, it is known that the founder's son and daughter are considering selling their stakes, as well as the stakes of their family members, including the largest shareholder, Shin Dong-guk, to global private equity funds (PEFs). Before the shareholders' meeting in March, Chairman Song had opposed the idea of selling management rights to overseas funds, drawing a line against the return of her children to management.
However, a representative of Director Im Jong-yoon's side stated, "While attracting 1 trillion won investment, which was pledged before the shareholders' meeting, is under consideration, the sale of shares for inheritance tax purposes is groundless."
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
